NASDAQ: EOLS
Evolus Inc Earnings Dates, Reports, Calls

Evolus earnings were -$62.0M for the trailing 12 months ending Jun 30, 2025, with N/A growth year over year. The latest EOLS earnings report on Jun 30, 2025 announced Q2 2025 earnings of -$17.1M, down 9.3% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, EOLS reported annual earnings of -$50.4M, with -18.3% growth.

EOLS earnings history

Current Revenue
$277.9M
Current Earnings
-$62.0M
Current Profit Margin
-22.3%

EOLS Return on Equity

Current Company
N/A
Current Industry
18%
Current Market
31.7%

EOLS undefined

Current Company
-27.4%
Current Industry
7%
EOLS is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when EOLS announces earnings.

EOLS undefined

Current Company
-24.44%
Current Industry
13.9%
EOLS has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

EOLS vs Pharmaceutical Stocks

TickerEBITDAEarningsY/Y EarningsEPS
EOLS-$33.58M-$62.00MN/A-$0.97
ETON-$273.00k-$4.58MN/A-$0.19
EBS$105.40M-$131.60MN/A-$2.54
ESPR-$32.50M-$104.02MN/A-$0.53
KMDA$34.21M$19.01M-7.60%$0.33

Evolus Earnings Reports & History FAQ

What were Evolus's earnings last quarter?

On EOLS's earnings call on Invalid Date, Evolus (NASDAQ: EOLS) reported Q2 2025 earnings per share (EPS) of -$0.27, up 50% year over year. Total EOLS earnings for the quarter were -$17.14 million. In the same quarter last year, Evolus's earnings per share (EPS) was -$0.18.

If you're new to stock investing, here's how to buy Evolus stock.

Is Evolus profitable or losing money?

As of the last Evolus earnings report, Evolus is currently losing money. Evolus's net profit (also called net income) for the twelve months ending Jun 30, 2025 was -$62.00 million, a 16.5% increase year over year.

What was EOLS's earnings growth in the past year?

As of Evolus's earnings date in Invalid Date, Evolus's earnings has grown year over year. EOLS earnings in the past year totalled -$62.00 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.